- Trials with a EudraCT protocol (381)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
381 result(s) found for: Hepatitis D.
Displaying page 7 of 20.
| EudraCT Number: 2012-001419-21 | Sponsor Protocol Number: TPVAHC2012 | Start Date*: 2013-08-15 |
| Sponsor Name:Universitätsklinikum Bonn | ||
| Full Title: An open label, randomised, non-inferiority trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatiti... | ||
| Medical condition: Acute Hepatitis C in HIV co-infection | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2012-002426-70 | Sponsor Protocol Number: 104005 | Start Date*: 2015-06-01 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: Phase III b, open, randomised, multicenter study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated po... | ||
| Medical condition: Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, polio, Haemophilus influenzae type b diseases. | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2019-002988-10 | Sponsor Protocol Number: 212645 | Start Date*: 2021-02-09 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:GlaxoSmithKline Biologicals SA | ||||||||||||||||||||||||||||||||||||||
| Full Title: A phase IV, single-blind, randomised, controlled, multi-country study to evaluate the immunogenicity and safety of GSK’s Infanrix hexa (DTPa-HBV-IPV/Hib) versus MCM Vaccine BV’s Vaxelis (DTaP5-HBV-... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Healthy volunteers [Primary and booster immunization of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b (... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) IT (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2018-004581-34 | Sponsor Protocol Number: FIHP201801 | Start Date*: 2019-04-02 |
| Sponsor Name:Fundación Instituto Hispalense de Pediatría | ||
| Full Title: An open-label Phase IV trial to evaluate the immunogenicity and safety of Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus infl... | ||
| Medical condition: Vaccines, Bacterial and viral vaccines combined | ||
| Disease: | ||
| Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-000554-46 | Sponsor Protocol Number: 106786 | Start Date*: 2006-08-09 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase II, observer-blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DSSITGDPa-HBV-IPV/Hib vaccine containing diphth... | ||
| Medical condition: Primary immunization of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b diseases. | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: FI (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2012-002427-15 | Sponsor Protocol Number: 105910 | Start Date*: 2015-06-01 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase III, partially double-blind clinical trial to evaluate the immu-nogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (new formulation) as co... | ||
| Medical condition: Primary immunization of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis diseases and, if applicable, Haemophilus influenzae type b disease. | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2012-002439-26 | Sponsor Protocol Number: 217744/100 | Start Date*: 2015-02-17 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: An open, multicentre, post-marketing surveillance (PMS) study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ DTPa-IPV/Hib vaccine administered at 3 and 4 months of age and ... | ||
| Medical condition: Primary immunization of healthy infants against diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b diseases. | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2012-000281-38 | Sponsor Protocol Number: LEG-SIL-LTX-05 | Start Date*: 2014-03-25 | |||||||||||
| Sponsor Name:Rottapharm | |||||||||||||
| Full Title: A Randomized, Controlled Study To Investigate The Efficacy, Safety And Pharmacokinetics Of Legalon® Sil, Alone Or In Combination With Ribavirin, For The Prevention Of Recurrent Hepatitis C In Liver... | |||||||||||||
| Medical condition: Recurrent Hepatitis C | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-002873-36 | Sponsor Protocol Number: A3L31 | Start Date*: 2016-07-08 |
| Sponsor Name:Sanofi Pasteur SA | ||
| Full Title: Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T Combined Vaccine at 2, 4, and 6 Months of Age versus Sanofi Pasteur's DTaP-IPV//PRP~T Combined Vaccine at 2, 4, and 6 Months of Ag... | ||
| Medical condition: Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Type b infection, Poliomyelitis, and Hepatitis B | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2004-001325-14 | Sponsor Protocol Number: 580299/008 | Start Date*: 2004-08-12 |
| Sponsor Name:GlaxoSmithKline SA | ||
| Full Title: Estudio en fase III, doble ciego, aleatorizado, controlado, multicéntrico para evaluar la eficacia de la vacuna HPV-16/18 VLP/AS04 de GlaxoSmithKline Biologicals comparada con la vacuna antihepatit... | ||
| Medical condition: cervical cancer => study is conducted in healthy female | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults | Gender: Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-004702-42 | Sponsor Protocol Number: RG101-04 | Start Date*: 2016-01-15 | ||||||||||||||||
| Sponsor Name:Regulus Therapeutics Inc. | ||||||||||||||||||
| Full Title: A Multi-Center, Parallel Group, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of a Single Subcutaneous Injection of RG-101 Combined with Oral GSK2878175 Taken Once Daily for 6, 9, o... | ||||||||||||||||||
| Medical condition: Treatment Naïve, Genotype 1 and 3, Chronic Hepatitis C Patients | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: HU (Completed) GR (Completed) ES (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2018-002368-18 | Sponsor Protocol Number: HEPB-VAC-01 | Start Date*: 2018-07-25 | |||||||||||||||||||||||||||||||
| Sponsor Name:FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR) | |||||||||||||||||||||||||||||||||
| Full Title: Phase IV, open, low-level intervention, clinical trial to compare the immunogenicity in immunosuppressed patients of an adjuvanted anti-hepatitis B vaccine with an anti-hepatitis B vaccine with inc... | |||||||||||||||||||||||||||||||||
| Medical condition: 1. Autoinmune rheumatic diseases undertreated by rituximab or infliximab. 2. breast and lung cancer undertreated by chemotherapy 3. HIV 4. Haematopoietic progenitor cell transplantation (TCPH). | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-004594-32 | Sponsor Protocol Number: IO102-IO103-013/MK3475-D18 | Start Date*: 2022-02-16 | |||||||||||
| Sponsor Name:IO Biotech ApS | |||||||||||||
| Full Title: An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (adv... | |||||||||||||
| Medical condition: Patients with previously untreated, unresectable or metastatic (advanced) melanoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IE (Prematurely Ended) BE (Trial now transitioned) HU (Trial now transitioned) PT (Completed) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-003428-34 | Sponsor Protocol Number: 103506 | Start Date*: 2015-05-04 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase IV, non-randomised, open-label, multicentre study with two parallel groups to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ combined DTPa-HBV-IPV/Hib vaccine ad... | ||
| Medical condition: Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b diseases. | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2020-003146-36 | Sponsor Protocol Number: RIAlta-1 | Start Date*: 2023-11-15 |
| Sponsor Name:Vall d'Hebron Research Institute (VHIR) | ||
| Full Title: Safety of Rifampicin at High Dose for the Treatment of Adult Subjects with Complex Drug Susceptible Pulmonary and Extrapulmonary Tuberculosis | ||
| Medical condition: Pulmonary and extrapulmonary tuberculosis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-002578-31 | Sponsor Protocol Number: X05-AR21-302 | Start Date*: 2005-09-14 |
| Sponsor Name:Sanofi Pasteur MSD S.N.C. | ||
| Full Title: A controlled, double-blind and randomized study, to compare the immunogenicity and safety of HEXAVAC manufactured by an upgraded process to HEXAVAC manufactured by the current process when given to... | ||
| Medical condition: The vaccine is indicated for primary and booster vaccination of children against six infectious diseases: diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis caused by 3 types of poliovirus ... | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-000898-30 | Sponsor Protocol Number: A5I19 | Start Date*: 2006-07-05 |
| Sponsor Name:Sanofi Pasteur Incorporated | ||
| Full Title: Safety and Immunogenicity of Booster Vaccination with PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conj... | ||
| Medical condition: PEDIACEL is a fully liquid combination vaccine indicated for infants and children for the prevention of five infectious diseases (diphtheria, tetanus, pertussis, poliomyelitis and infections caused... | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2022-003923-17 | Sponsor Protocol Number: SH600008 | Start Date*: 2023-01-26 | ||||||||||||||||
| Sponsor Name:Sanofi Pasteur | ||||||||||||||||||
| Full Title: Safety and Immunogenicity Study of Full Schedule (3-Dose of Shan6™) or Shan6™-Shan5®-Shan6™ Versus the Licensed Vaccine Shan5® With bOPV (bivalent oral polio vaccine) and IPV (inactivated poliomyel... | ||||||||||||||||||
| Medical condition: | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: Outside EU/EEA | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2013-003427-10 | Sponsor Protocol Number: 111157 | Start Date*: 2015-05-04 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase III, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) administered to I... | ||
| Medical condition: Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, polio and Hib diseases. | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2013-004304-19 | Sponsor Protocol Number: 117119 | Start Date*: 2015-07-23 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa™ vaccine when administered to healthy infants as primary v... | ||
| Medical condition: Active immunization against diphtheria, tetanus, pertussis infection caused by all known subtypes of hepatitis B virus, poliomyelitis, and invasive disease caused by Haemophilus influenzae type B (... | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
